Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice

Author:

Abushahba Mostafa F.12ORCID,Dadelahi Alexis S.1,Lemoine Emily L.1,Skyberg Jerod A.1,Vyas Swati3,Dhoble Sagar3,Ghodake Vinod3,Patravale Vandana B.3,Adamovicz Jeffrey J.14

Affiliation:

1. Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA

2. Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Assiut University, Assiut 71515, Egypt

3. Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga (E), Mumbai 400019, Maharashtra, India

4. Laboratory for Infectious Disease Research, University of Missouri, Columbia, MO 65211, USA

Abstract

Brucellosis is a zoonotic disease that causes significant negative impacts on the animal industry and affects over half a million people worldwide every year. The limited safety and efficacy of current animal brucellosis vaccines, combined with the lack of a licensed human brucellosis vaccine, have led researchers to search for new vaccine strategies to combat the disease. To this end, the present research aimed to evaluate the safety and efficacy of a green vaccine candidate that combines Brucella abortus S19 smooth lipopolysaccharide (sLPS) with Quillaja saponin (QS) or QS-Xyloglucan mix (QS-X) against mucosal brucellosis in BALB/C mice. The results of the study indicate that administering two doses of either sLPS-QS or sLPS-QS-X was safe for the animals, triggered a robust immune response, and enhanced protection following intranasal challenge with S19. Specifically, the vaccine combinations led to the secretion of IgA and IgG1 in the BALF of the immunized mice. We also found a mixed IgG1/IgG2a systemic response indicating evidence of both Th1 and Th2 activation, with a predominance of the IgG1 over the IgG2a. These candidates resulted in significant reductions in the bioburden of lung, liver, and spleen tissue compared to the PBS control group. The sLPS-QS vaccination had conferred the greatest protection, with a 130-fold reduction in Brucella burdens in lung and a 55.74-fold reduction in the spleen compared to PBS controls. Vaccination with sLPS-QS-X resulted in the highest reduction in splenic Brucella loads, with a 364.6-fold decrease in bacterial titer compared to non-vaccinated animals. The study suggests that the tested vaccine candidates are safe and effective in increasing the animals’ ability to respond to brucellosis via mucosal challenge. It also supports the use of the S19 challenge strain as a safe and cost-effective method for testing Brucella vaccine candidates under BSL-2 containment conditions.

Funder

Bill & Melinda Gates Foundation

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference61 articles.

1. The New Global Map of Human Brucellosis;Pappas;Lancet Infect. Dis.,2006

2. (2020, November 14). Signs and Symptoms | Brucellosis | CDC, Available online: https://www.cdc.gov/brucellosis/symptoms/index.html.

3. Laboratory Diagnosis of Human Brucellosis;Yagupsky;Clin. Microbiol. Rev.,2020

4. Sero-Diagnosis of Brucellosis in Sheep and Humans in Assiut and El-Minya Governorates, Egypt;Abdelbaset;Int. J. Vet. Sci. Med.,2018

5. Identification of Potential Antigenic Peptides of Brucella through Proteome and Peptidome;Pei;Vet. Med. Sci.,2023

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3